common.study.topics.clinical

Subclinical Cardiovascular Disease in Psoriatic Disease

common.study.values.description

Subclinical Cardiovascular Disease in Psoriatic Disease

This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk. The Aim of this study is to 1) Evaluate the association between moderate to severe psoriatic disease and measures of vascular function. 2) Evaluate the association between moderate to severe psoriatic disease and measures of thrombotic risk. 3) Understand how traditional medications used in cardiovascular disease (CVD) prevention such as aspirin and statins affect vascular function and thrombotic risk in those with moderate to severe psoriatic disease.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Aspirin and/or Atorvastatin

This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.

participant.views.study.view.additional

participant.views.study.view.scientific-title

Subclinical Cardiovascular Disease in Psoriatic Disease

common.study.values.clinical-trial-id

NCT03228017

participant.views.study.view.id

negj6d